Wedbush Downgrades Sunesis Pharmaceuticals To Neutral, Shares Drop

Analysts at Wedbush downgraded Sunesis Pharmaceuticals

from Outperform to Neutral. Sunesis Pharmaceuticals shares have jumped 57.81% over the past 52 weeks, while the S&P 500 index has surged 21.89% in the same period. Sunesis Pharmaceuticals' shares fell 3.60% to $7.50 in pre-market trading.